Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Die Bedeutung von Therapiezielen in der Onkologie (1997)
    Springer
    Der Onkologe 3 (1997), S. S29 
    Details
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Die moderne Medizin mit ihrer Tendenz zur Spezialisierung und zur Fokussierung auf die naturwissenschaftliche Sicht der Erkrankungen neigt zur Vernachlässigung des subjektiven Krankheitserlebnisses des Patienten. Dies löst bei dem Betroffenen häufig Unbehagen, manchmal Furcht aus, insbesondere bei einer so existentiell bedrohenden Erkrankung wie Krebs. Therapieziele in der Onkologie werden für den betroffenen Patienten daher formuliert, um das Behandlungskonzept schlüssig, transparent sowohl für den Arzt als auch den Patient nachvollziehbar zu gestalten. Grundsätzliche Therapieziele sind die Kuration einerseits und die Palliation von Tumorerkrankungen auf der anderen Seite. Diese übergeordneten Ziele sind allerdings nicht nur bei der Erstdiagnose zu konzipieren, sondern sie müssen während des Krankheitsverlaufs immer wieder neu überdacht und unter Berücksichtigung des medizinischen Fortschritts, vor allem aber auch angesichts der jeweils individuellen Krankheitsentwicklung gegebenenfalls ersetzt oder umformuliert werden.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/PL00008330
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Synthese von neuen bifunktionellen Maleinimidverbindungen zur Herstellung von Chemoimmunokonjugaten (1997)
    Springer
    Monatshefte für Chemie 128 (1997), S. 91-102 
    Details
    ISSN: 1434-4475
    Keywords: Maleimides ; Chemoimmunoconjugates ; Crosslinking reagent
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Summary Bifunctional maleimide compounds are suitable for binding small molecules to carrier proteins in that they bind to the sulfhydryl group of proteins through the double bond of the maleimide group and to molecules of low molecular weight (e.g. anticancer drugs) through a functional groupX. 18 maleimide compounds of the general formula Maleimid-R-X (R=phenylene, benzyl-, methylene-, ethylene, or am-benzoylethylamide group andX=hydroxy-, amino-, hydrazino-, carboxylic acid-, carboxylic anhydride-, carboxylic acid chloride-, carboxylic acid hydrazide-, oxycarbonylchloride-, aldehyde, keto-, orp-toluenesulfonate-group) were synthesized and characterized through1H- and13C-NMR-spectroscopy, elemental analysis, and mass spectrometry.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00807643
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Clinical phase I study with one-hour paclitaxel infusion (1998)
    Springer
    Annals of oncology 9 (1998), S. 569-572 
    Details
    ISSN: 1569-8041
    Keywords: paclitaxel (Taxol®) ; phase I study ; toxicity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Paclitaxel (PAC) is one of the major anti-cancer drugs,effective in different tumors. Studies with 24-hour infusion with 135mg/m2 and a three-hour infusion with 175 mg/m2showed a significant schedule-dependent toxicity. We evaluated a one-hourinfusion schedule within a phase I study to determine the dose limitingtoxicity (DLT), the maximum tolerated dose (MTD), and the anti-cancerefficacy. Patients and methods: Patients with advanced malignant tumors weretreated within cohorts by one-hour infusional paclitaxel starting with 150mg/m2 and stepwise escalation with 25 mg/m2increments. Therapy was repeated in three-week intervals. Cycles wererepeated until progression. Toxicity was closely monitored, anti-cancerefficacy was only evaluated in those patients who received at minimum twotreatment cycles. Results: Thirty-four patients entered the study (11 NSCLC, five SCLC,seven ovarian cancer, one cervix cancer, nine MBC, one HN cancer). The MTDwas PAC 250 mg/m2. The DLT was central and peripheralneuropathy (WHO grade 3). Other significant toxicities were fatigue,myalgia/arthralgia and paraesthesia. No significant myelotoxicity wasobserved. Totally twentyone patients were evaluable for response. A partialresponse was observed in five (24%) patients (two NSCLC, two ovariancancer, one head and neck cancer). Three (14%) patients had stabledisease and in 13 (62%) patients progressive disease was observed. Conclusions: Paclitaxel 225 mg/m2 on day 1 administered asone-hour infusion and repeated every three weeks can be given safely, featuredno relevant myelotoxicity, and is the recommended dose for phase II studies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008217429971
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Clinical and pharmacologic phase I study of Cemadotin—HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer (1998)
    Springer
    Annals of oncology 9 (1998), S. 1323-1330 
    Details
    ISSN: 1569-8041
    Keywords: Cematodin–HCL ; Dolastin 15 analog ; phase I study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: To determine the maximum tolerable dose (MTD), principal toxicity, and pharmacologic behaviour of Cemadotin—HCl, a novel antimitotic peptide. Patients and methods: Cemadotin—HCl (10.0 to 27.5 mg/m2/day every three weeks) was administered as a 24-hour intravenous (i.v.) continuous infusion to patients with advanced cancer. Pharmacokinetic analyses were performed during the first treatment cycle. Blood samples were taken over 48 hours and analyzed by radioimmunoassay. Results: Hypertension was the dose-limiting toxicity (DLT). This type of toxicity was observed at all dose levels, but grade 3 (CTC) was observed only at dose levels 20.0, 25.0 and 27.5 mg/m2. This effect was reversible but in three patients associated with signs of cardiac ischemia. Other significant toxic effects were neutropenia, asthenia, tumor pain and transient liver enzyme elevation. A linear pharmacokinetics was observed. The best curve fit was obtained with a two-compartment model with a terminal half-life of ≈10 hours at each dose level, a volume of distribution at steady state of ≈9 l/m2 and a total clearance of ≈0.6 l/hour/m2. Neither partial nor complete responses were observed although minor tumor regressions were seen in a patient with carcinoma of unknown primary (CUP) and in another patient with liver metastases from a colon cancer. Conclusions: Hypertension was the dose-limiting toxicity of Cemadotin—HCl administered as a continuous 24-hour infusion. The recommended dose for further evaluation of its anticancer efficacy in disease-oriented phase II studies with this schedule is 15.0 mg/m2. The nature of the principal cardio-vascular toxicity remains unclear. The observed toxicities appeared to be significant but manageable.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008430515881
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...